» Articles » PMID: 30546075

Post-translational Modifications of Beclin 1 Provide Multiple Strategies for Autophagy Regulation

Overview
Specialty Cell Biology
Date 2018 Dec 15
PMID 30546075
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

Autophagy is a conserved intracellular degradation pathway essential for protein homeostasis, survival and development. Defects in autophagic pathways have been connected to a variety of human diseases, including cancer and neurodegeneration. In the process of macroautophagy, cytoplasmic cargo is enclosed in a double-membrane structure and fused to the lysosome to allow for digestion and recycling of material. Autophagosome formation is primed by the ULK complex, which enables the downstream production of PI(3)P, a key lipid signalling molecule, on the phagophore membrane. The PI(3)P is generated by the PI3 kinase (PI3K) complex, consisting of the core components VPS34, VPS15 and Beclin 1. Beclin 1 is a central player in autophagy and constitutes a molecular platform for the regulation of autophagosome formation and maturation. Post-translational modifications of Beclin 1 affect its stability, interactions and ability to regulate PI3K activity, providing the cell with a plethora of strategies to fine-tune the levels of autophagy. Being such an important regulator, Beclin 1 is a potential target for therapeutic intervention and interfering with the post-translational regulation of Beclin 1 could be one way of manipulating the levels of autophagy. In this review, we provide an overview of the known post-translational modifications of Beclin 1 that govern its role in autophagy and how these modifications are maintained by input from several upstream signalling pathways. ▓.

Citing Articles

C118P Suppresses Gastric Cancer Growth via Promoting Autophagy-Lysosomal Degradation of RAB1A.

Wei S, Zhang J, Wu H, Liao Z, Liu Z, Hou Y Pharmaceutics. 2025; 16(12.

PMID: 39771598 PMC: 11678531. DOI: 10.3390/pharmaceutics16121620.


Modulating Autophagy in Osteoarthritis: Exploring Emerging Therapeutic Drug Targets.

Andrei C, Mihai D, Nitulescu G, Nitulescu G, Zanfirescu A Int J Mol Sci. 2025; 25(24.

PMID: 39769455 PMC: 11727697. DOI: 10.3390/ijms252413695.


Regulatory Mechanisms Governing the Autophagy-Initiating VPS34 Complex and Its inhibitors.

Lee Y, Tuan N, Lee G, Kim B, Park J, Lee C Biomol Ther (Seoul). 2024; 32(6):723-735.

PMID: 39370737 PMC: 11535298. DOI: 10.4062/biomolther.2024.094.


Network analysis and experimental verification of Salvia miltiorrhiza Bunge-Reynoutria japonica Houtt. drug pair in the treatment of non-alcoholic fatty liver disease.

Chen H, Yan S, Xiang Q, Liang J, Deng X, He W BMC Complement Med Ther. 2024; 24(1):305.

PMID: 39143459 PMC: 11325759. DOI: 10.1186/s12906-024-04600-4.


Role of AMBRA1 in mitophagy regulation: emerging evidence in aging-related diseases.

Di Rienzo M, Romagnoli A, Refolo G, Vescovo T, Ciccosanti F, Zuchegna C Autophagy. 2024; 20(12):2602-2615.

PMID: 39113560 PMC: 11587829. DOI: 10.1080/15548627.2024.2389474.


References
1.
Bento C, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M . Mammalian Autophagy: How Does It Work?. Annu Rev Biochem. 2016; 85:685-713. DOI: 10.1146/annurev-biochem-060815-014556. View

2.
Dikic I, Elazar Z . Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018; 19(6):349-364. DOI: 10.1038/s41580-018-0003-4. View

3.
Farre J, Subramani S . Mechanistic insights into selective autophagy pathways: lessons from yeast. Nat Rev Mol Cell Biol. 2016; 17(9):537-52. PMC: 5549613. DOI: 10.1038/nrm.2016.74. View

4.
Rubinsztein D, Bento C, Deretic V . Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med. 2015; 212(7):979-90. PMC: 4493419. DOI: 10.1084/jem.20150956. View

5.
Lamb C, Yoshimori T, Tooze S . The autophagosome: origins unknown, biogenesis complex. Nat Rev Mol Cell Biol. 2013; 14(12):759-74. DOI: 10.1038/nrm3696. View